← Back to Screener
ABBVIE INC. (ABBV)
Price$203.71
Favorite Metrics
Price vs S&P 500 (26W)-18.44%
Price vs S&P 500 (4W)-8.73%
Market Capitalization$364.98B
P/E Ratio (Annual)86.37x
Indicated Dividend Yield (Annual)3.40%
All Metrics
P/CF (Annual)19.18x
Book Value / Share (Quarterly)$0.80
P/TBV (Annual)455.35x
Indicated Dividend (Annual)$6.56
Revenue Growth (3Y)1.75%
Cash Flow / Share (Quarterly)$10.08
Payout Ratio (TTM)275.84%
Price vs S&P 500 (YTD)-14.78%
Gross Margin (TTM)71.62%
Net Profit Margin (TTM)6.91%
EPS (TTM)$2.38
10-Day Avg Trading Volume6.29M
EPS Excl Extra (TTM)$2.38
Revenue Growth (5Y)5.95%
EPS (Annual)$2.38
Dividend / Share (Annual)$6.60
ROI (Annual)6.07%
Gross Margin (Annual)71.62%
Net Profit Margin (5Y Avg)12.88%
Cash / Share (Quarterly)$2.97
P/E Basic Excl Extra (TTM)86.37x
Revenue Growth QoQ (YoY)10.04%
EPS Growth (5Y)-2.88%
P/E Normalized (Annual)86.37x
ROA (Last FY)3.15%
Revenue Growth TTM (YoY)8.57%
EBITD / Share (TTM)$5.67
ROE (5Y Avg)70.88%
Operating Margin (TTM)24.65%
Cash Flow / Share (Annual)$10.08
P/B Ratio257.03x
P/B Ratio (Quarterly)261.01x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)6.99x
Net Interest Coverage (TTM)3.46x
ROA (TTM)3.12%
EPS Growth QoQ (YoY)-88.08%
EV / EBITDA (TTM)42.54x
EPS Incl Extra (Annual)$2.38
Current Ratio (Annual)0.67x
Quick Ratio (Quarterly)0.41x
3-Month Avg Trading Volume6.82M
52-Week Price Return17.76%
EV / Free Cash Flow (Annual)23.98x
P/E Incl Extra (TTM)86.37x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.14
P/S Ratio (Annual)5.97x
Asset Turnover (Annual)0.46x
52-Week High$244.81
Operating Margin (5Y Avg)25.49%
EPS Excl Extra (Annual)$2.38
CapEx CAGR (5Y)8.75%
26-Week Price Return-11.55%
Quick Ratio (Annual)0.41x
13-Week Price Return-6.02%
Total Debt / Equity (Annual)20.19x
Current Ratio (Quarterly)0.67x
Enterprise Value$427,251.12
Revenue / Share Growth (5Y)4.73%
Asset Turnover (TTM)0.45x
Book Value / Share Growth (5Y)-10.06%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)3.80x
Pretax Margin (Annual)10.79%
Cash / Share (Annual)$2.97
3-Month Return Std Dev25.32%
Gross Margin (5Y Avg)69.76%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)9.38%
EBITDA Interim CAGR (5Y)-13.63%
ROE (Last FY)128.66%
Net Interest Coverage (Annual)3.46x
EPS Basic Excl Extra (Annual)$2.38
P/FCF (TTM)20.49x
Receivables Turnover (TTM)5.20x
EV / Free Cash Flow (TTM)23.98x
Total Debt / Equity (Quarterly)49.22x
EPS Incl Extra (TTM)$2.38
Receivables Turnover (Annual)5.20x
ROI (TTM)5.66%
Dividend Growth Rate (5Y)6.76%
P/S Ratio (TTM)5.97x
Pretax Margin (5Y Avg)15.04%
Revenue / Share (Annual)$34.50
Tangible BV / Share (Annual)$0.14
Forward P/E14.43x
Free OCF CAGR (5Y)1.19%
Price vs S&P 500 (52W)-16.87%
P/E Ratio (TTM)86.37x
EPS Growth TTM (YoY)-1.30%
Year-to-Date Return-10.85%
5-Day Price Return-3.12%
EPS Normalized (Annual)$2.38
ROA (5Y Avg)5.27%
Net Profit Margin (Annual)6.91%
Month-to-Date Return-6.34%
Cash Flow / Share (TTM)$8.66
EBITD / Share (Annual)$5.67
EPS Growth (3Y)-28.99%
Operating Margin (Annual)24.65%
LT Debt / Equity (Annual)18.14x
P/CF (TTM)19.18x
ROI (5Y Avg)8.99%
P/E Excl Extra (TTM)86.37x
LT Debt / Equity (Quarterly)45.44x
EPS Basic Excl Extra (TTM)$2.38
P/TBV (Quarterly)455.35x
Payout Ratio (Annual)275.84%
P/B Ratio (Annual)94.44x
Dividend / Share (TTM)$6.60
Inventory Turnover (TTM)3.80x
Pretax Margin (TTM)10.79%
Book Value / Share (Annual)$1.88
Price vs S&P 500 (13W)-8.40%
Net Margin Growth (5Y)-7.27%
Dividend Yield (TTM)3.19%
Beta0.29x
P/FCF (Annual)20.49x
Revenue / Share (TTM)$34.44
ROE (TTM)95.59%
52-Week Low$168.54
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.92
3.86
3.87
3.90
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share) | 1.40x | 69.14% | 72.55% | -8.08% | $47.99 |
About
AbbVie is a diversified pharmaceutical company with core franchises in immunology (Humira, Skyrizi, Rinvoq) and oncology (Imbruvica, Venclexta), complemented by a growing aesthetics business anchored by Botox following the 2020 Allergan acquisition. Recent 2024 acquisitions of Cerevel Therapeutics and Immunogen strengthen its neuroscience and oncology pipelines. The company's multi-therapeutic portfolio leverages established market positions and provides diversified revenue streams.